Amorchem
Amorchem is a private equity and venture capital firm established in 1997 and based in Montreal, Canada. The firm focuses on investing in the life sciences sector, particularly in genomics, biotechnology, and therapeutics for diseases such as cancer, infectious diseases, inflammation, and diabetes. Amorchem primarily targets promising life science projects originating from universities and research centers in Quebec, employing an innovative model that finances research-stage projects to achieve pre-clinical proof-of-concept. The firm invests in various forms, including common stock and convertible securities, and often seeks a Board seat to actively participate in the growth of its portfolio companies. Amorchem's investment strategy emphasizes both early-stage and later-stage financing, and while it may act as a sole investor, it generally prefers to engage in syndicated deals. The firm primarily operates in Canada, the United States, and Europe, with a commitment to maximizing the commercial potential of quality academic research.
Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, focused on developing innovative peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists. Founded in 2015, the company aims to address various health conditions, including Prader-Willi syndrome, Type-1 diabetes, obesity, and other metabolic disorders such as non-alcoholic steatohepatitis. Inversago's approach seeks to overcome limitations associated with earlier generations of CB1 blockers, thereby maximizing their therapeutic potential. By advancing new drug candidates, Inversago Pharma is positioned to provide healthcare professionals and patients with effective treatment options for metabolic and fibrotic disorders.
Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, focused on developing innovative peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists. Founded in 2015, the company aims to address various health conditions, including Prader-Willi syndrome, Type-1 diabetes, obesity, and other metabolic disorders such as non-alcoholic steatohepatitis. Inversago's approach seeks to overcome limitations associated with earlier generations of CB1 blockers, thereby maximizing their therapeutic potential. By advancing new drug candidates, Inversago Pharma is positioned to provide healthcare professionals and patients with effective treatment options for metabolic and fibrotic disorders.
SemaThera is a spin-off company from AmorChem Venture Fund 1, focusing on SEMA 3A protein inhibitor in the treatment of ocular diseases, such as diabetic macular edema. This technology emerges from the laboratory of Dr Mike Sapieha, Hôpital Maisonneuve-Rosement (Montreal, Canada).